Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071 [PMID: 18932287 DOI: 10.3748/wjg.14.6065]
Corresponding Author of This Article
Quan Zhou, Associate Professor, Department of Clinical Pharmacy, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Province 310009, China. zhouquan142602@zju.edu.cn
Article-Type of This Article
Rapid Communication
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 21, 2008; 14(39): 6065-6071 Published online Oct 21, 2008. doi: 10.3748/wjg.14.6065
Table 1 Details of prescriptions of the two clarithromycin products
Clarithromycin
Sustained-release
Immediate release
Total number of prescriptions
949
197
Number of prescriptions for alimentary disease
164
110
Mean age (range) yr
45.9 (18-82)
Male:Female
137:137
Number of prescriptions for anti-H pylori therapy
159
96
Triple therapy
151
83
PPI/Clarithromycin/Amoxicillin
43
58
PPI/Clarithromycin/Furazolidone
44
21
PPI/Clarithromycin/Levofloxacin
63
1
PPI/Clarithromycin/Metronidazole
1
1
PPI/Clarithromycin/Tinidazole
0
2
Quadruple therapy
5
6
PPI/Bismuth/Amoxicillin/Clarithromycin
0
2
PPI/Bismuth/ Furazolidone/Clarithromycin
1
3
PPI/Bismuth/Levofloxacin/Clarithromycin
4
1
Dual therapy
3
7
Clarithromycin/PPI
2
7
Clarithromycin/Ranitidine bismuth citrate
1
0
Table 2 Diagnoses of patients on clarithromycin-based therapy
Diagnoses
Clarithromycin
SR
IR
Chronic gastritis
90
87
Peptic ulcer
40
5
Duodenal ulcer
9
5
Gastro-oesophageal reflux disease
5
1
Chronic gastritis, H pylori infection
4
3
Gastric ulcer
1
4
Chronic gastritis, Gastric ulcer
2
1
Gastro-oesophageal reflux disease, Gastric ulcer
1
H pylori infection
2
Chronic gastritis, Peptic ulcer
1
3
Peptic ulcer, H pylori infection
1
Mesenteric lymphadenitis
7
Abdominal pain of unknown origin
2
Table 3 Concomitant drugs used in clarithromycin-based triple therapy
Comedicated drugs
Clarithromycin
SR
IR
PPI
Omeprazole
17
6
Lansoprazole
68
6
Pantoprazole
30
66
Esomeprazole magnesium
15
11
Rebeprazole
23
21
Antibiotics
Amoxicillin
38
63
Furazolidone
47
24
Levofloxacin
67
2
Metronidazole
1
1
Tinidazole
0
13
Amoxicillin/clavulanate potassium
5
0
Table 4 CYP3A based clinical significant drug interactions with clarithromycin
Concurrent medications primarily metabolized by CYP3A
Clarithromycin
References
SR
IR
Alprazolam and zolpidem
1
[6,7]
Midazolam
1
[6,8]
Amlodipine
1
2
[9]
Levoamlodipine
1
Nifedipine
1
[10]
Carbamazepine
1
[11]
Nifedipine, clopidogrel and atorvastatin
1
[10,12-14]
Amlodipine and ergoloid mesylate sustained release capsules
1
[9,15]
Prednisone
1
[16]
Citation: Zhou Q, Zhu LL, Yan XF, Pan WS, Zeng S. Drug utilization of clarithromycin for gastrointestinal disease treatment. World J Gastroenterol 2008; 14(39): 6065-6071